[The role of combined treatment of prostatic gland after biopsy of the prostate for an elevated PSA level].
Benign prostatic hyperplasia and prostatic cancer have a significant effect of men's health, quality of life and death rate. Recent researches propose algorithms for treatment of benign prostatic hyperplasia which help determine optimal management of the disease using either alpha-adrenoblocker or combined therapy basing on factors of progression risk. Molecular-genetic, biological investigations reveal pathological prosesses leading to onset of the above pathological conditions thus opening prospects for prophylaxis of both benign and malignant prostatic hyperplasia. Further studies will specify efficacy and safety of 5-alpha reductase inhibitors in prevention of prostatic cancer.
Okhrits
V E
VE
bogdanov
A B
AB
Veliev
E I
EI
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage*; D000368:Aged; D000465:Algorithms; D001706:Biopsy; D004791:Enzyme Inhibitors / Q000008:administration & dosage*; D018120:Finasteride / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood*; D011470:Prostatic Hyperplasia / Q000097:blood / Q000188:drug therapy / Q000473:pathology; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy / Q000473:pathology; D012189:Retrospective Studies; D013449:Sulfonamides / Q000008:administration & dosage*; D000077409:Tamsulosin
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists; D004791:Enzyme Inhibitors; D013449:Sulfonamides; D018120:Finasteride; D017430:Prostate-Specific Antigen; D000077409:Tamsulosin